Two breakthrough therapy-designated novel biologics provided highlight among recent applications for US FDA approval. ImmunityBio’s interleukin-15 superagonist candidate aims to provide a secondary boost to augment the immunological response elicited by Bacillus Calmette-Guerin therapy for bladder cancer, while CSL Limited and uniQure N.V. plan to bring gene therapy to the treatment of hemophilia B.
AbbVie Inc. returned to Parkinson’s disease mainstay treatment carbidopa/levodopa with a prodrug formulation, ABBV-951, designed to be the first...





